Pain management

First Clinical Study Validates the Impact of Personalized Music on Youth with Chronic Pain by The Songs of Love Foundation

Retrieved on: 
Thursday, February 15, 2024
Simmons University, Empowerment, Adolescent medicine, Chronic pain, Pain management, Nociception, Music, Song, Songs of Love, Research

The Songs of Love Foundation, a national nonprofit 501(c)(3) organization, has been dedicated to creating free, personalized, original songs for children and teens facing tough medical, physical, or emotional challenges for over 28 years.

Key Points: 
  • The Songs of Love Foundation, a national nonprofit 501(c)(3) organization, has been dedicated to creating free, personalized, original songs for children and teens facing tough medical, physical, or emotional challenges for over 28 years.
  • The study, titled "The acceptability of Songs of Love for youth living with chronic pain," marks a pivotal moment for The Songs of Love Foundation, demonstrating the effectiveness of personalized music as a complementary intervention for pain management.
  • It involved interviews with 15 youth who received a personalized song and six singer-songwriters who created the songs, exploring the program's acceptability from both perspectives.
  • The positive feedback from both the youth participants and the singer-songwriters involved in the study highlights the transformative power of personalized music."

NRMP® Specialties Matching Service® Matched Nearly 12,000 Applicants into Fellowship Programs for the 2024 Appointment Year

Retrieved on: 
Tuesday, February 13, 2024
BSN, Metabolism, Medicine, Growth, Diabetes, Pain management, Doctor of Health Science, MBA, Brain damage, SMS, Gynecologic Oncology (journal), NRMP, Urogynecology, Interventional pulmonology, Forensic pathology, Result, Emergency medical services, Medical genetics, Workforce, Sports medicine, Critical Care Medicine (journal), Nursing

WASHINGTON, Feb. 13, 2024 /PRNewswire/ -- The National Resident Matching Program® (NRMP®) has released a new data report, the Results and Data Specialties Matching Service®, 2024 Appointment Year, for Fellowship Matches in the Specialties Matching Service® (SMS®). The report shows that 14,034 active applicants submitted a rank order list of programs, competing for 14,169 fellowship positions in 6,116 programs. Of those applicants, 11,853 were matched to a fellowship position, an increase of 305 active applicants from the 2023 appointment year.  

Key Points: 
  • The report shows that 14,034 active applicants submitted a rank order list of programs, competing for 14,169 fellowship positions in 6,116 programs.
  • Of those applicants, 11,853 were matched to a fellowship position, an increase of 305 active applicants from the 2023 appointment year.
  • The number of applicants matched for the 2024 appointment year increased for all applicant types compared to 2023.
  • The number of U.S. MD graduates matched was 6,667, an increase of 110 applicants from the 2023 appointment year.

B. Braun Launches Heparin Sodium 2,000 Units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL)

Retrieved on: 
Tuesday, February 13, 2024
Sodium chloride, DEHP, PVC, Patient, Pain management, Medical device

BETHLEHEM, Pa., Feb. 13, 2024 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), the fifth product in its portfolio of Heparin premixed bags.

Key Points: 
  • BETHLEHEM, Pa., Feb. 13, 2024 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), the fifth product in its portfolio of Heparin premixed bags.
  • This new addition to the portfolio enhances the Company's ability to serve the diverse needs of healthcare facilities and their patients for this high-alert medication.
  • The B. Braun Heparin portfolio is manufactured using EXCEL® IV Containers which are not made with natural rubber latex, DEHP or PVC, placing a priority on patient and environmental safety.
  • Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.

RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine

Retrieved on: 
Tuesday, February 13, 2024
Therapy, NINDS, RespireRx, GABAA, NIH, Neuropathic pain, Epilepsy, Addiction, Neuron, Narcotic, Female, Rat, OTC Markets Group, Drug discovery, Analgesic, Disability studies, Interim, University, PSPP, Pain management, Chronic pain, Research fellow, Patient, Heart, Initiative, Male, Hypoventilation, IND, DRS, Laboratory, Research, Pharmaceutical industry

Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management.

Key Points: 
  • Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management.
  • The PSPP program, part of the NIH HEAL Initiative, evaluates non-opioid assets in a battery of established preclinical pain models.
  • These observations were made with both male and female rats in two measures each, in models of post-incision pain and spinal nerve ligation-induced persistent neuropathic pain.
  • These data trigger the advancement of KRM-II-81 within the NIH PSPP program where additional disease-specific pain models will be evaluated.

Bimini Hydrotherapy Unveils the Next Generation of Cold Plunge Hydrotherapies for Home Use

Retrieved on: 
Thursday, February 8, 2024
JuJu Smith-Schuster, Athlete, Temperature, Inflammation, Pain management, Skin, Injury, Oxygen, Health, NFL, Juju, Hydrotherapy, Fatigue, NBA, Water, Super Bowl, Entrepreneurship, Dallas Cowboys

HOUSTON, Feb. 8, 2024 /PRNewswire-PRWeb/ -- Bimini Hydrotherapy announces the release of its first at-home unit, the Bimini NanoJet® Eco, turning a bathtub into an oxygen perfusion system to help recover from sports injuries and aid in cellular rejuvenation. The device is the next generation in hydrotherapies by making oxygen more readily available, helping with inflammation treatment, pain management, sleep issues, fatigue, skin conditions and anti-aging.

Key Points: 
  • The device is the next generation in hydrotherapies by making oxygen more readily available, helping with inflammation treatment, pain management, sleep issues, fatigue, skin conditions and anti-aging.
  • "We're in a league of our own when it comes to ultra-fine nanobubbles for deep tissue rejuvenation for transdermal oxygen hydrotherapy," said Co-Founder Rick Applewhite.
  • The Bimini NanoJet Oxygen Perfusion System is a technological breakthrough for oxygen perfusion into the body's soft cell tissue using ultra-fine nanobubbles.
  • The Bimini NanoJet System is the only oxygen perfusion system that can produce nanobubbles as small as 0.02 microns.

Sichenzia Ross Ference Carmel LLP Closes Over 100 Capital Markets Transactions Valued At Over $700 Million in 2023

Retrieved on: 
Thursday, February 8, 2024
Pain management, Growth, Stroke, MWG, SRFC, IPO, Security (finance)

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Today, Sichenzia Ross Ference Carmel LLP (“SRFC”), a full-service law firm internationally recognized for its securities and litigation practices, announced that it has closed over 100 transactions, ranging from $1.1 million to $70 million. In 2023, with the total value of these transactions surpassing $700 million. The transactions on behalf of both issuers and underwriters included initial public offerings, secondary public offerings, registered direct offerings and private placements.

Key Points: 
  • NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Today, Sichenzia Ross Ference Carmel LLP (“SRFC”), a full-service law firm internationally recognized for its securities and litigation practices, announced that it has closed over 100 transactions, ranging from $1.1 million to $70 million.
  • In 2023, with the total value of these transactions surpassing $700 million.
  • The transactions on behalf of both issuers and underwriters included initial public offerings, secondary public offerings, registered direct offerings and private placements.
  • In October of 2023, Sichenzia Ross Ference LLP combined forces with Carmel, Milazzo & Feil to form SRFC and currently consists of approximately 70 experienced attorneys in offices including New York City, California and Florida.

CAPC Announces the Winners of its New York City Tipping Point Challenge

Retrieved on: 
Wednesday, February 7, 2024
MPA, Caregiver, Patient, CAPC, Communication, Challenge, Pain management, Palliative care, Nursing

NEW YORK, Feb. 7, 2024 /PRNewswire-PRWeb/ -- The Center to Advance Palliative Care (CAPC) has proudly announced the winners in its New York City Tipping Point Challenge.

Key Points: 
  • NEW YORK, Feb. 7, 2024 /PRNewswire-PRWeb/ -- The Center to Advance Palliative Care (CAPC) has proudly announced the winners in its New York City Tipping Point Challenge.
  • The New York City-based competition was part of CAPC's third National Tipping Point Challenge funded by The John A. Hartford Foundation.
  • "I am proud that our New York City Tipping Point Challenge provided a catalyst for clinicians to enhance their clinical skills through CAPC courses," said CAPC CEO, Brynn Bowman, MPA.
  • Winners in the New York City Tipping Point Challenge are:

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

Retrieved on: 
Wednesday, February 7, 2024
PRV, Steroid, Prostate cancer, COGS, Contingent value rights, TLX, Palliative care, Osteosarcoma, Patient, Safety, Nephrotoxicity, QSAM, FDA, Appendix, Sarcoma, Food, Term sheet, Brain, Disease, Pain management, Acquisition, Metastasis, Samarium, ODD, Radiopharmaceutical, Aplastic anemia, Glioma, ASX, Priority review, Medical imaging

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).

Key Points: 
  • MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).
  • QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.
  • Telix believes that 153Sm-DOTMP may benefit patients with metastatic lung and breast cancer, where many patients develop brain and bone metastases, and disease management often focusses on quality-of-life palliative care.
  • Telix will issue ordinary shares to the stockholders of QSAM at closing within its Listing Rule 7.1 placement capacity as consideration for the acquisition.

San Jose Wellness Center, NexGen Health, Elevates Wellness Offerings with the Introduction of BPC 157 Peptide Therapy

Retrieved on: 
Wednesday, February 7, 2024
NexGen, IBD, Inflammation, SAN, Tears, Regenerative medicine, Wound, Regeneration, Wound healing, Inflammatory bowel disease, Patient, Irritable bowel syndrome, BPC, Abrasion, Arthritis, IBS, Health, Pain management, Quality of life, Tropical ulcer, Arthralgia

SAN JOSE, Calif., Feb. 7, 2024 /PRNewswire/ -- NexGen Health, a prominent wellness clinic located in San Jose, California, is pleased to announce the integration of BPC 157 Peptide Therapy into its comprehensive suite of specialized wellness services. This cutting-edge therapy is poised to invigorate the body's innate healing processes, offering renewed hope to individuals seeking optimal health and well-being.

Key Points: 
  • NexGen Health improves patient care by introducing BPC 157 peptide therapy in San Jose, California, empowering healing, and wellness.
  • SAN JOSE, Calif., Feb. 7, 2024 /PRNewswire/ -- NexGen Health, a prominent wellness clinic located in San Jose, California, is pleased to announce the integration of BPC 157 Peptide Therapy into its comprehensive suite of specialized wellness services.
  • "Our commitment to offering BPC 157 Peptide Therapy reflects our passion for providing our patients with the latest advancements in regenerative medicine," says Ilbra Petros, Director of NexGen Health.
  • Our commitment to offering BPC 157 Peptide Therapy reflects our passion for providing our patients with the latest advancements in regenerative medicine," says Ilbra Petros, Director of NexGen Health.

CAPC Announces the Winners of its Third The John A. Hartford Foundation Tipping Point Challenge

Retrieved on: 
Wednesday, February 7, 2024
CAPC, Palliative care, Clinical, Caregiver, Patient, Winners, MPA, Honors student, Communication, Challenge, Pain management, Training, Organization, Nursing

NEW YORK, Feb. 7, 2024 /PRNewswire-PRWeb/ -- The Center to Advance Palliative Care (CAPC) has proudly announced the winners in the "Clinical Training" category of its third Tipping Point Challenge. This national Challenge, sponsored by CAPC and The John A. Hartford Foundation, was the culmination of CAPC's five-year campaign aimed at creating a tipping point in the improvement of care delivered to millions of Americans living with a serious illness.

Key Points: 
  • NEW YORK, Feb. 7, 2024 /PRNewswire-PRWeb/ -- The Center to Advance Palliative Care (CAPC) has proudly announced the winners in the "Clinical Training" category of its third Tipping Point Challenge.
  • This national Challenge, sponsored by CAPC and The John A. Hartford Foundation, was the culmination of CAPC's five-year campaign aimed at creating a tipping point in the improvement of care delivered to millions of Americans living with a serious illness.
  • View the Winners and Honor Roll at https://tippingpointchallenge.capc.org/winners-finalists/
    "I am proud that our John A. Hartford Foundation Tipping Point Challenge provided a catalyst for clinicians from all specialties and disciplines to enhance their skills through CAPC courses," said CAPC CEO, Brynn Bowman, MPA.
  • CAPC is honored to play a part in the achievement of better outcomes for patients, families, and caregivers."